547 filings
Page 2 of 28
8-K
nsm0yw6r1l33f n43r
24 Oct 23
PTN - Palatin Announces $5 Million Registered Direct Offering
4:05pm
424B5
362czeb
24 Oct 23
Prospectus supplement for primary offering
2:38pm
8-K
9ps1t d7j
19 Oct 23
Palatin Announces Preliminary Quarter Ended
8:01am
8-K
fg5to2trjvyk86u4rxth
13 Oct 23
Palatin Receives Notice of Non-Compliance from NYSE American
4:31pm
8-K
mccf7
28 Sep 23
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial
8:02am
8-K
0frkv4
8 Sep 23
Palatin to Present at the H.C. Wainwright
8:00am
8-K
55dxl0
7 Sep 23
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
8:49am
8-K
kx77vryu658xx0 fp11
10 Aug 23
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
8:15am
8-K
0kvm8a5zc
8 Aug 23
Palatin Provides Update on VYLEESI® Collaborations
8:00am
8-K
lryy6mkwhs83q6e4oe0y
7 Aug 23
Other Events
8:00am
8-K
wi7b 0tl74
4 Aug 23
Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
8:00am
8-K
dqpkbjr
11 Jul 23
Palatin Announces Preliminary Fourth Quarter Fiscal 2023
8:25am
8-K
2vqkrzmdg53nmgq
21 Jun 23
Submission of Matters to a Vote of Security Holders
9:01am
8-K
ccusxeudf 1hc
30 May 23
Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
9:30am
8-K
01jvvt8v5xjkjy9tgi0j
16 May 23
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
8:15am
8-K
ua3 c8jbi7dgca3az
12 May 23
Other Events
8:44am
8-K
63cor0 bav
9 May 23
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
8:19am